Transcranial magnetic stimulation has evolved from relatively standardized protocols into increasingly sophisticated treatment strategies involving accelerated schedules, individualized targeting, altered dosing, medications, and behavioral interventions. New interventional psychiatry research is now raising an important question: as these protocols become more advanced, do researchers know which individual components are actually responsible for their clinical effects?
A new paper published online in Brain Stimulation on August 13, 2026, proposes a framework designed to answer that question. Rather than evaluating complex TMS protocols only as complete treatment packages, the authors argue that researchers should increasingly examine their individual components.
Why Modern TMS Protocols Are Becoming Harder To Interpret
TMS is no longer defined by a single stimulation parameter. A treatment protocol can differ by coil design, frequency, dose, treatment duration, targeting method, brain region, session acceleration, medication use, and behavioral interventions.
The researchers note that even if each of nine components had only two possible settings, there would already be 512 potential configurations.
That flexibility creates opportunities for innovation, but it also creates a scientific challenge. When several variables change simultaneously and outcomes improve, researchers may know that the overall protocol works without knowing which changes produced the improvement.
A New Framework For TMS Treatment Optimization
The authors propose what they call component-controlled TMS research. The goal is to design studies that isolate individual protocol variables whenever feasible, allowing investigators to determine whether specific components contribute independently to treatment outcomes.
Central to the proposal is a new Component Control Index, or CCI. The CCI represents the proportion of manipulated treatment components that have an appropriate comparison allowing their individual effects to be evaluated. Scores range from 0, indicating no component control, to 1, indicating full component control.
The authors also propose a graphical Component Map showing which elements of a TMS protocol were changed, which were adequately controlled, and which remain intertwined with other variables.
Why Separating Treatment Components Matters
Consider an accelerated TMS protocol that simultaneously changes stimulation dose, treatment schedule, and targeting method. If patients improve, all three changes may be contributing, or one may account for much of the effect.
Component-controlled research could begin separating those possibilities.
The paper points to recent accelerated protocols as examples of this challenge. Some approaches simultaneously alter dosing, acceleration, targeting, or pharmacological augmentation, making it difficult to determine the contribution of each individual element.
This distinction matters because identifying active components could eventually help researchers simplify protocols, improve efficiency, and determine where additional complexity genuinely adds clinical value.
From Demonstrating Efficacy To Understanding The Protocol
Importantly, the proposed CCI is not intended to rank studies or determine whether a treatment is effective. A low CCI does not mean a study is poor quality, and a high CCI does not prove that researchers understand the biological mechanism involved.
Instead, the index addresses a narrower question: how confidently can a study attribute an observed effect to a particular treatment component?
The authors envision this as part of the research lifecycle. An innovative bundled protocol can first establish proof of concept. Subsequent studies can then systematically dismantle the package to identify which elements should be retained, modified, or potentially removed.
Precision TMS May Require Precision Trial Design
This proposal arrives as the broader TMS field increasingly explores individualized targeting, accelerated stimulation, alternative dosing strategies, and combination treatments. Updated consensus recommendations already recognize these approaches as important areas of ongoing investigation while emphasizing the need for further research.
For clinics and patients, the framework does not immediately change how TMS should be delivered. Its implications are primarily for researchers designing the next generation of trials.
Over time, however, better component-level evidence could influence clinical practice by helping determine which protocol features deliver meaningful benefit and which add complexity without sufficient additional value.
Building More Interpretable TMS Protocols
The authors do not argue that researchers should stop developing sophisticated multicomponent treatments. Instead, they propose pairing innovation with a deliberate effort to understand what makes successful protocols work.
That could become increasingly important as TMS moves toward greater personalization. The next phase of TMS treatment optimization may depend not only on creating more advanced protocols, but also on identifying their most valuable ingredients.
Citations
- Messner AR, Adams TG, Arnold EM, Rakesh G. Unbundling Transcranial Magnetic Stimulation (TMS) treatment protocols: Standardized reporting for component controlled trials. Brain Stimulation. Published online August 13, 2026. DOI: 10.1016/j.brs.2026.103184. Brain Stimulation Article
- Trapp NT, Purgianto A, Taylor JJ, et al. Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology. 2025;170:206-233. DOI: 10.1016/j.clinph.2024.12.015. PubMed Record
Explore more at https://www.interventionalpsychiatry.org/
